BeyondSpring Inc. (BYSI)

US — Healthcare Sector
Peers: SRZN  ARMP  KTTA  ONCT  ADTX  SCPH  MIST  ONCY  MCRB  LIFE  KA  CADL  INKT  FBRX  ALVR    OCUP  RVPH  PLX  EYPT  SLS 

Automate Your Wheel Strategy on BYSI

With Tiblio's Option Bot, you can configure your own wheel strategy including BYSI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BYSI
  • Rev/Share -0.0109
  • Book/Share -0.3142
  • PB -2.4211
  • Debt/Equity -0.0193
  • CurrentRatio 2.4892
  • ROIC -0.2582

 

  • MktCap 68537710.0
  • FreeCF/Share -0.512
  • PFCF -3.3205
  • PE 334.3305
  • Debt/Assets 0.0147
  • DivYield 0
  • ROE -0.0067

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting
BYSI
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

FLORHAM PARK, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it presented interim phase 2 data on the 303 Study, a study in 2L/3L non-small cell lung cancer (NSCLC) after disease progression on 1L PD-1/L1 inhibitors with and without chemotherapy (NCT05599789), with financial support from Merck's (Rahway, NJ USA) Investigator Studies Program and provision of study drug, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, on May 31st, 2025 in Chicago, IL.

Read More
image for news BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

About BeyondSpring Inc. (BYSI)

  • IPO Date 2017-03-09
  • Website https://www.beyondspringpharma.com
  • Industry Biotechnology
  • CEO Dr. Lan Huang Ph.D.
  • Employees 40

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.